Replication Protein A (RPA) Binding to Duplex Cisplatin-damaged
DNA Is Mediated through the Generation of Single-stranded DNA*
Steve M.
Patrick
and
John J.
Turchi§
From the Department of Biochemistry and Molecular Biology, Wright
State University School of Medicine, Dayton, Ohio 45435
 |
ABSTRACT |
Replication protein A (RPA) is a heterotrimeric
protein composed of 70-, 34-, and 14-kDa subunits that has been shown
to be required for DNA replication, repair, and homologous
recombination. We have previously shown preferential binding of
recombinant human RPA (rhRPA) to duplex cisplatin-damaged DNA compared
with the control undamaged DNA (Patrick, S. M., and Turchi,
J. J. (1998) Biochemistry 37, 8808-8815). Here we
assess the binding of rhRPA to DNA containing site-specific
cisplatin-DNA adducts. rhRPA is shown to bind 1.5-2-fold better to a
duplex 30-base pair substrate containing a single 1,3d(GpXpG) compared
with a 1,2d(GpG) cisplatin-DNA intrastrand adduct, consistent with the
difference in thermal stability of DNA containing each adduct.
Consistent with these data, a 21-base pair DNA substrate containing a
centrally located single interstrand cisplatin cross-link resulted in
less binding than to the undamaged control DNA. A series of experiments
measuring rhRPA binding and concurrent DNA denaturation revealed that
rhRPA binds duplex cisplatin-damaged DNA via the generation of
single-stranded DNA. Single-strand DNA binding experiments show that
rhRPA binds 3-4-fold better to an undamaged 24-base DNA compared with
the same substrate containing a single 1,2d(GpG) cisplatin-DNA adduct. These data are consistent with a low affinity interaction of rhRPA with
duplex-damaged DNA followed by the generation of single-stranded DNA
and then high affinity binding to the undamaged DNA strand.
 |
INTRODUCTION |
Cisplatin, cis-diamminedichloroplatinum(II), is a
chemotherapeutic drug used to treat a variety of cancers. A major
clinical limitation of cisplatin treatment is the development of
cellular resistance (1, 2). The cytotoxic action is believed to involve the formation of covalent DNA-adducts which block the enzymes involved
in replication and transcription (reviewed in Ref. 3). The drug forms
1,2d(GpG), 1,2d(ApG), and 1,3d(GpXpG) intrastrand adducts as well as
interstrand DNA cross-links (4, 5). Each adduct bends and distorts the
DNA structure in a unique manner (5-9) and has been suggested to be
recognized and repaired at different rates (10). These unique DNA
structural distortions induced by the cisplatin adducts are believed to
be responsible for the differential repair and may individually
influence protein recognition, which could ultimately lead to
differential metabolism of damaged DNA. Proteins that bind to
cisplatin-damaged DNA have been implicated as important components in
the sensitivity of cells to cisplatin treatment (4). By understanding
how each individual DNA adduct is repaired and understanding the
mechanisms of protein recognition, the development of better
DNA-targeted chemotherapeutic drugs is possible.
The nucleotide excision-repair
(NER)1 pathway is responsible
for the removal of intrastrand cisplatin-DNA adducts as well as other
bulky adduct damage and must display a higher affinity for damaged DNA
in the vast background of undamaged DNA (reviewed in Ref. 11). The use
of xeroderma pigmentosum cell lines, which are deficient in NER, has
led to the isolation and characterization of the human proteins
required for NER (12). The entire NER pathway has now been
reconstituted using purified proteins (13, 14). The XPA and RPA
proteins have been implicated in the initial recognition of damaged DNA
and have been shown to interact in the absence of DNA (15, 16).
Independently, both XPA and RPA have been shown to exhibit preferential
binding to damaged DNA and in conjunction a synergistic effect on
binding was observed (17-19). Recently, the p34 subunit of RPA has
been shown to be responsible for the XPA interaction and stimulation of
XPA UV-damaged DNA binding (20). Support for RPA mediating the
subsequent NER reactions has been obtained in vitro where
RPA interacts with the XPG and XPF-ERCC1 proteins (19, 21, 22). It has
also been shown that RPA can enhance the binding and nuclease
activities of XPG and XPF-ERCC1 to bubble and loop substrates (21).
Other reports suggest that RPA may protect the nondamaged strand from incision by XPG and XPF-ERCC1 during NER (23, 24). The mechanism of
damaged strand incision discrimination, however, has not been defined.
Our data support a role for RPA regulating the incision of the damaged
DNA strand by binding the single-stranded DNA opposite the DNA adduct.
This would support the hypothesis that RPA protects the undamaged
strand from cleavage by XPG and XPF-ERCC1.
We have previously purified a protein that binds cisplatin-damaged DNA,
DRP-3 (25). Comparison of the protein subunits, the complexes formed
between DNA, and EMSA supershift analysis confirmed that DRP-3 is RPA.
We have also shown, by EMSA analysis, that rhRPA preferentially binds
duplex cisplatin-damaged DNA compared with the undamaged control DNA
dependent upon salt concentration (25). Here we show that rhRPA binding
increases with moderate levels of cisplatin-DNA damage before excess
DNA damage results in decreased rhRPA binding. Increasing cisplatin-DNA
damage also results in the formation of cisplatin-DNA interstrand
cross-links. We have assessed binding and denaturation to a series of
substrates containing site-specific cisplatin-DNA adducts and have
correlated binding with denaturation. Experiments using bubble
substrates and single-stranded DNA suggest that RPA recognizes the
structural distortion in the DNA and not specifically the cisplatin-DNA
adduct. These data support the hypothesis that RPA binds duplex-damaged DNA, denatures the unstable region near the adduct, and then binds the
single-stranded DNA opposite the adduct to regulate DNA repair. These
results are discussed with respect to RPA binding and the regulation of
cisplatin-DNA repair.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Oligonucleotides were purchased from Integrated
DNA Technologies, Inc. (Coralville, IA) and purified by 15%
polyacrylamide, 7 M urea preparative sequencing gel
electrophoresis. Radiolabeled nucleotides were from NEN Life Science
Products and unlabeled nucleotides were from Amersham Pharmacia
Biotech. T4 polynucleotide kinase was purchased from New England
Biolabs (Beverly, MA). Sequenase (version 2.0) was purchased from
U. S. Biochemical Corp. Mung bean nuclease was from Life Technologies,
Inc. Cisplatin was purchased from Sigma. All other reagents were from
the standard suppliers.
Protein Purification--
The rhRPA expression vector was kindly
provided by Marc Wold and purified as described previously (26).
DNA Substrates--
The duplex 44-bp DNA was prepared by
annealing the complementary 25-mer depicted in Table
I and extended using Sequenase, [
-32P]dGTP, and dNTPs (27). The substrate was
subsequently purified on a 15% native gel followed by treatment with
mung bean nuclease to ensure that no contaminating single-stranded DNA
was present and purified by spin column chromatography (25). The
platination reactions were separate for each individual substrate and
described in the platination section below. The 30-base DNA
oligonucleotides used to prepare the 1,2d(GpG) and 1,3d(GpXpG)
substrates as well as the sequences for the other oligonucleotides are
shown in Table I. The 30-bp DNA substrates were 5'-labeled using T4
polynucleotide kinase and [
-32P]ATP and, following
platination, annealed to the complementary oligonucleotides, which are
depicted as either 1,2-C or 1,3-C in Table I. The bubble substrates
were prepared similarly, but following labeling and platination, the
1,3d(GpXpG) oligonucleotide was annealed to the 1,2d(GpG) complementary
oligonucleotide, 1,2-C, to give an 8-base bubble substrate. The
interstrand cross-link substrtate was prepared from the I.C.
(interstrand cross-link) oligonucleotide depicted in Table I and its
complementary DNA, I.C.-C. The 19-base oligonucleotide, I.C., was
designed to have a 2-base overhang when annealed to the complement
I.C.-C, so that one could extend the substrate to yield a duplex 21-bp
DNA. The 21-bp interstrand cross-link substrate was prepared by using
the 19-mer, I.C., platinating at a 1:1 D/N ratio (drug to nucleotide ratio), annealing the complementary 19-mer, I.C.-C, incubating the
annealed substrate in 0.1 M NaClO4 for 15 h at 37 °C, purified by ion-exchange chromatography using Qiagen
resin (Chatsworth, CA), and subsequently extended with Sequenase
and dNTPs. The platinated duplex substrate was then purified on a 10%
polyacrylamide, 7 M urea preparative gel. The
cisplatin-interstrand cross-linked DNA migrated with a molecular mass
of 40-45 nucleotides and was excised from the gel, eluted, and
ethanol-precipitated. Both the unplatinated and platinated substrates
were run on a 15% native gel to separate the duplex from any
contaminating single-stranded DNA and subsequently treated with mung
bean nuclease and labeled with T4 polynucleotide kinase and
[
-32P]ATP (28). The 24-base DNA with a single
1,2d(GpG) cisplatin-DNA adduct was 5'-labeled using T4 kinase and
[
-32P]ATP, platinated, and purified on a 18%
sequencing gel to separate the undamaged DNA from the DNA reacted with
cisplatin (29). All the undamaged control DNA substrates were prepared
identically except for the omission of cisplatin.
DNA Platination--
The 44-bp DNA substrates were treated with
varying concentrations of cisplatin ranging from D/N ratios of 0:1-5:1
in 1 mM NaHPO4 (pH 7.5) and 3 mM
NaCl for 16-20 h at 37 °C in the dark. Drug to nucleotide ratios
refer to the molar amount of cisplatin to the molar amount of
nucleotides within a given substrate. The DNA was purified from
unreacted cisplatin by G-50 spin column chromatography or ethanol
precipitation followed by washing with 70% ethanol (30). The 30-base
DNA substrates (1,2 and 1,3) were 5'-labeled with
[
-32P]ATP and T4 polynucleotide kinase, platinated at
1:1 D/N ratios, and annealed to the complementary oligonucleotide
followed by treatment with either HaeIII or AciI
for the 1,2d(GpG) or 1,3d(GpXpG) cisplatin-DNA adducts, respectively,
and were subsequently purified on a 15% native gel. This ensures that
100% of the substrate was platinated. The undamaged control DNA
substrates were not digested with restriction enzymes. The counts per
minute recovered was determined by liquid scintillation counting an
aliquot of the eluate, and on the basis of the specific activity, the
picomoles of DNA recovered was calculated.
Electrophoretic Mobility Shift Assay and Denaturation
Experiments--
EMSAs were performed as described previously (27).
Reactions were performed with 50 fmol of DNA in the presence of 50 mM NaCl and in the presence or absence of 2 mM
MgCl2 as indicated in the figure legends. Reaction products
were separated by either 4 or 6% native gels. Gels were dried and
quantified by PhosphorImager analysis as described previously (25). For
the denaturation experiments, EMSA reactions were split in half and
half analyzed by EMSA analysis and the other half terminated by the
addition of 0.1% Orange G dye, 25 mM EDTA, 0.5% SDS, and
5 mg of proteinase K to denature the protein-DNA interaction and allow
the separation of duplex and single-stranded DNA. These products were
then analyzed on 15% native gels and quantified by PhosphorImager analysis.
 |
RESULTS |
Analysis of rhRPA Binding a Duplex 44-bp DNA with Increasing
Cisplatin-DNA Damage--
Previously, we have shown that rhRPA
preferentially binds a duplex 44-bp DNA globally treated with cisplatin
at a D/N ratio of 0.2:1 compared with the undamaged control DNA of
identical sequence dependent on salt concentration (25). To determine the effect of increasing cisplatin-DNA damage on rhRPA binding, the
same 44-bp DNA was treated with increasing amounts of cisplatin and
binding assessed in an EMSA (Fig.
1A). The DNA was purified as
described under "Experimental Procedures" and contained no contaminating single-stranded DNA as evident by native gel analysis (data not shown). The increase in cisplatin-DNA adducts distorts the
DNA structure, resulting in a decreased mobility of the free DNA in the
gel (lanes 1-6) (31). It was anticipated that increasing cisplatin-DNA damage would result in an increase in rhRPA binding, similar to the observation of RPA binding UV-damaged DNA (18). In
reactions containing 50 mM NaCl and no MgCl2,
however, rhRPA binding reached a peak at intermediate cisplatin-DNA
damage before a decrease in rhRPA binding was observed (lanes
1-6). The presence of MgCl2 shifted the peak to the
right, but still resulted in a decrease in rhRPA binding with higher
levels of cisplatin-DNA damage (data not shown). Quantification of the
binding results reveals about a 10-fold enhanced binding of rhRPA to
the DNA damaged with a D/N ratio of 0.2:1 compared with the
undamaged DNA (Fig. 1B), consistent with that reported
previously (25). A decrease in RPA binding of 30% was observed from
the peak of binding obtained at a D/N of 0.2 to that observed at a D/N
of 5.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
RPA binding to a duplex 44-bp DNA with
increasing cisplatin-DNA adducts. A, EMSAs were
performed using 50 fmol of duplex 44-bp DNA, 50 ng (425 fmol) of rhRPA,
and buffer containing 50 mM NaCl (lanes 1-6).
The duplex DNAs used in the reactions were purified as described under
"Experimental Procedures" to ensure no contaminating
single-stranded DNA was present. Lane 1 is undamaged duplex
DNA; lanes 2-6 represent D/N of 0.1:1, 0.2:1, 0.5:1, 1:1,
and 5:1, respectively. B, quantification of the rhRPA
binding data from A is presented and represents the average
of two individual experiments. The error bars represent the
range of values.
|
|
The observation that rhRPA binding decreases at higher cisplatin-DNA
damage is in contradiction to the results that increased rhRPA binding
was observed to DNA with increasing UV DNA damage (18). The enhanced
binding of RPA to UV-damaged DNA was suggested to be the result of
binding to the single-stranded nature in the DNA structure caused by
the UV-induced (6-4) photoproduct (18). The interaction of cisplatin
with DNA results in a variety of adducts, some of which increase
single-strand generation and those that prevent single-stranded DNA
formation. Sequencing gel analysis of the duplex 44-bp DNA (Fig.
2) shows an increase in the formation of
cisplatin-DNA interstrand cross-links with increasing cisplatin-DNA damage (lanes 1-7). Lane 2 represents
contaminating DNA that was purified away through native gel
purification and is most likely incompletely extended DNA that occurred
during the substrate preparation. The covalent bond formed between the
platinum and the N7 positions of the guanines on two complementary DNA
strands, cisplatin-interstrand cross-link, inhibits the denaturation of
the two strands and results in a complex with a molecular weight about
twice that expected (indicated by the brace, I.C.). The
formation of DNA interstrand cross-links could be responsible for the
decreased ability of rhRPA to bind/denature the duplex 44-bp DNA. At
the highest level of cisplatin-DNA damage, greater than 80% of the DNA
has at least one interstrand cross-link. The sequence of the duplex
44-bp DNA reveals that the interstrand cross-links can form at both
ends of the DNA at three specific dGdC sites. All three sites are
within 7 bases of either terminus. This would still allow rhRPA to bind in the central region of the DNA and may be the reason why rhRPA binding is not completely inhibited at the highest level of
cisplatin-DNA damage.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 2.
Interstrand cross-links are preferentially
formed on the duplex 44-bp DNA treated at high cisplatin levels.
The same duplex 44-bp DNA substrates used in Fig. 1 were separated by
DNA sequencing gel electrophoresis and visualized by autoradiography as
described under "Experimental Procedures." The undamaged DNA is in
lane 1, and lane 2 is the undamaged DNA
contaminant that was removed during the purification of the DNA
substrate. Lanes 3-7 represent D/N ratio of 0.1:1, 0.2:1,
0.5:1, 1:1, and 5:1, respectively. I.C. refers to the
cisplatin-interstrand cross-linked DNA.
|
|
rhRPA Binding Is Inhibited by Cisplatin-Interstrand
Cross-links--
Considering the results correlating the percent
interstrand cross-links with a decrease in rhRPA binding, we assessed
binding of rhRPA to a DNA substrate containing a single site-specific, centrally located cisplatin-interstrand DNA cross-link (Fig.
3A). The 21-bp DNA was
constructed as described previously (28) and purified to remove any
contaminating single-stranded DNA (see "Experimental Procedures").
Approximately 95% of the substrates purified via this method contained
an interstrand cross-link (data not shown). EMSA analysis revealed that
increasing rhRPA concentrations resulted in a low level of rhRPA
binding to the undamaged duplex control DNA substrate (lanes
1-5), and interestingly, even lower levels of rhRPA binding to
the DNA substrate containing a single cisplatin-DNA interstrand
cross-link (lanes 5-10). Quantification of the EMSA is
shown in Fig. 3B. The high level of rhRPA binding the
undamaged control DNA is likely the result of decreased stability of
the 21-bp DNA. Increasing the duplex DNA length increases the DNA
stability and decreases the nonspecific rhRPA binding as can be seen
when comparing the undamaged 21-bp DNA, a 25-bp undamaged DNA, and the
undamaged 30-bp DNA (data not shown). The inability of rhRPA to bind a
substrate containing a cisplatin-interstrand cross-link is consistent
with rhRPA binding occurring via denaturation of the duplex DNA. We do
observe a low level of rhRPA binding to the interstrand cross-link DNA,
which could be the result of the 5% contaminating duplex undamaged DNA
or an extremely low affinity for DNA containing a cisplatin-interstrand
cross-link.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
A single interstrand cisplatin-DNA adduct
inhibits the ability of rhRPA to bind duplex DNA. A,
EMSAs were performed in buffer supplemented with 2 mM
MgCl2 and 50 mM NaCl using 50 fmol of 21-bp
undamaged DNA (lanes 1-5) or the same 21-bp DNA containing
a single interstrand cisplatin cross-link (lanes 6-10).
Lanes 1 and 6, without added rhRPA; lanes
2 and 7, 50 ng (425 fmol); lanes 3 and
8, 100 ng (850 fmol); lanes 4 and 9,
150 ng (1.27 pmol); lanes 5 and 10, 200 ng (1.7 pmol). The products were separated on a 6% native polyacrylamide gel.
B, quantification of increasing concentrations of rhRPA
binding undamaged ( ) or cisplatin-damaged ( ) duplex 21-bp DNA.
The results presented are the average of two individual experiments,
and error bars represent the range of values.
|
|
rhRPA Binding Correlates with the Ability to Denature
Cisplatin-damaged DNA--
RPA has been shown to denature undamaged
DNA substrates, including long stretches of duplex DNA dependent on the
ionic strength (32, 33). RPA has also been shown to bind and denature
DNA substrates containing an SV40 "pseudo-origin" of replication
(34). In order to assess whether the denaturation ability of rhRPA was responsible for the preferential binding observed to duplex
cisplatin-damaged DNA compared with duplex undamaged DNA, a series of
experiments were performed with the duplex undamaged and 0.1:1
cisplatin-treated DNA substrates measuring both DNA binding (data not
shown) and DNA denaturation (Fig.
4A). Separation of reaction
products was achieved using a 15% native gel in the denaturation
experiments. In addition, SDS and proteinase K were added to the stop
buffer to denature the protein and disrupt the protein-DNA interaction. The 4% native gels used in the EMSAs do not resolve single-strand from
duplex DNA and also do not distinguish between rhRPA bound to duplex
versus single-stranded DNA. Increasing rhRPA concentrations resulted in minimal generation of single-stranded DNA for the undamaged
control DNA (lanes 1-6) under these experimental
conditions, while an increase in single-stranded DNA was observed for
the cisplatin-damaged DNA (lanes 7-12). The quantification
(Fig. 4B) reveals that rhRPA binding to duplex DNA
correlates with an increase in the generation of single-stranded DNA.
These data suggest that rhRPA binding to cisplatin-damaged DNA is
mediated through the ability to bind duplex DNA and generate
single-stranded DNA to which rhRPA binds with high affinity. Divalent
cations, including Mg2+, have been shown to wind and
stabilize duplex DNA (35). The NaCl and MgCl2 stabilize the
duplex-undamaged DNA and inhibit rhRPA binding/denaturation, while the
cisplatin adducts destabilize the DNA structure largely independent of
ionic strength.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 4.
Denaturation of duplex 44-bp DNA by rhRPA
correlates with binding activity. A, denaturation
experiments were performed under identical conditions as the EMSAs
using the duplex 44-bp DNA, but the reaction stop buffer contained SDS
and proteinase K to disrupt the protein-DNA interaction, and the
products were run on a 15% native gel to separate duplex from
single-stranded DNA. Lanes 1 and 7 are the
heat-denatured controls, , for the undamaged and 0.1:1
cisplatin-damaged 44-bp DNA, respectively. Lanes 2 and
8, depicted by C are the no enzyme controls for
the undamaged and cisplatin-damaged DNA. Lanes 3 and
9, 25 ng of rhRPA (212 fmol); lanes 4 and
10, 50 ng of rhRPA (425 fmol); lanes 5 and
11, 100 ng of rhRPA (850 fmol); lanes 6 and
12, 200 ng of rhRPA (1.7 pmol). B, quantification
of increasing concentrations of rhRPA denaturing ( , ) and binding
( , ) the undamaged ( and , respectively) and the
cisplatin-damaged ( and , respectively) 44-bp DNA in the presence
of 50 mM NaCl.
|
|
rhRPA Binds Preferentially to Cisplatin-DNA Intrastrand
Adducts--
If rhRPA binding is proportional with the thermal
instability of the DNA duplex, DNA substrates with varying thermal
stabilities should result in varying degrees of binding by RPA.
Therefore, DNA substrates were designed containing either a single
site-specific 1,2d(GpG) or 1,3d(GpXpG) cisplatin-DNA adduct. The 1,2 adduct induces a bend and unwinds the duplex DNA, but results in no
localized single-stranded DNA (36). In contrast, the 1,3 adduct results in a localized denaturation of approximately 2 bases around the adduct
(37, 38). We have shown previously a 4-6-fold preference for rhRPA
binding a duplex 25-bp DNA containing a single 1,2d(GpG) cisplatin-intrastrand DNA adduct compared with the same undamaged substrate (25). Here we have designed longer substrates for rhRPA
binding analysis of both types of intrastrand adducts in order to
increase the stability of the DNA and decrease the nonspecific binding
of rhRPA to the undamaged DNA. The 30-bp substrates used for the
cisplatin-intrastrand rhRPA binding experiments were prepared as
described under "Experimental Procedures" and were completely devoid of any contaminating single-stranded DNA. The binding reactions were conducted in the presence of 50 mM NaCl and 2 mM MgCl2 to minimize damage-independent binding
(Fig. 5). Increasing rhRPA concentrations
resulted in minimal rhRPA binding to the undamaged 30-bp DNA (data not
shown), while an increase in the amount of rhRPA bound was observed
using the same substrate with a single 1,2d(GpG) cisplatin-DNA adduct
(Fig. 5A, lanes 1-5). Quantification of the
results reveals up to 10-fold enhanced binding of rhRPA to the
1,2d(GpG) duplex-damaged DNA compared with the undamaged control (Fig.
5B, filled and open circles,
respectively). Fig. 5A also shows the EMSA analysis of
increasing concentrations of rhRPA binding the same substrate with a
single 1,3d(GpXpG) cisplatin-DNA adduct (lanes 6-10).
Quantification reveals greater than 15-fold enhanced binding of rhRPA
to the 1,3d(GpXpG) cisplatin-DNA adduct compared with the undamaged
control DNA of identical sequence in the linear ranges of the graph
(Fig. 5B, filled and open squares, respectively). The quantification also reveals about a 1.5-2-fold preferential binding to the 1,3d(GpXpG) cisplatin-DNA intrastrand adduct compared with the 1,2d(GpG) cisplatin-DNA intrastrand adduct under identical binding conditions (filled squares and
filled circles, respectively). As seen with the 44-bp DNA,
the binding of rhRPA to the 30-bp DNAs correlates with the ability to
denature the DNA substrate (data not shown). These data suggest that
the unique structural distortions induced by the individual intrastrand adducts influence rhRPA binding. The differential binding of rhRPA to
different DNA adducts could ultimately be responsible for the differential repair rates that have been shown previously for these two
types of cisplatin-DNA intrastrand adducts (10). These data are
consistent with a role for RPA in the initial steps of the NER process
(19).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 5.
rhRPA binding correlates with the instability
of the cisplatin-damaged duplex DNA. A, EMSAs were
performed using the following indicated amounts of rhRPA and 50 fmol of
either the 30-bp 1,2 adduct (lanes 1-5) or 1,3 adduct
(lanes 6-10) in the presence of 2 mM
MgCl2 and 50 mM NaCl. The products were
separated on a 4% native polyacrylamide gel and visualized by
autoradiography. Lanes 1 and 6, without added
rhRPA; lanes 2 and 7, 25 ng (212 fmol);
lanes 3 and 8, 50 ng (425 fmol); lanes
4 and 9, 100 ng (850 fmol); lanes 5 and
10, 200 ng (1.7 pmol). B, quantification of
increasing rhRPA concentrations binding undamaged ( , ), 1,2d(GpG)
( ), or 1,3d(GpXpG) ( ) cisplatin-damaged DNA. The results
presented are the average of two individual experiments, and
error bars represent the range of values.
|
|
rhRPA Binds the Structural Distortion in the DNA and Not Directly
to the Cisplatin-DNA Adduct--
The results from the cisplatin damage
titration (Fig. 1) and the differential binding of rhRPA to substrates
containing a cisplatin 1,2d(GpG) and a 1,3d(GpXpG) intrastrand DNA
adduct (Fig. 5) suggest that rhRPA is binding the structural distortion
and not specifically to the cisplatin-DNA adduct. To address this hypothesis, DNA substrates containing 8-base bubbles were designed to
further assess the binding specificity of rhRPA on duplex DNA substrates. The 30-bp bubble substrates were prepared as described under "Experimental Procedures," and denaturation experiments ensured the substrates were devoid of contaminating single-stranded DNA
(data not shown). EMSAs were performed with 50 fmol of DNA and
increasing concentrations of rhRPA under the conditions stated under
"Experimental Procedures," and the results are shown in Fig.
6A. The substrates used for
the EMSA were the duplex 30-bp DNA with a single 1,3d(GpXpG)
cisplatin-DNA adduct (data not shown), a 30-bp undamaged DNA with an
8-base bubble (lanes 1-5), and the same 8-base bubble
substrate with a single 1,3d(GpXpG) cisplatin-DNA adduct located within
the bubble region (lanes 6-10). Results from the
quantification show an increase in rhRPA binding to the 30-bp DNA with
a single 1,3d(GpXpG) cisplatin-DNA adduct (filled circles)
consistent with that presented earlier (Fig. 5B). The binding of rhRPA to the undamaged 8-base bubble substrate (filled squares), however, is 3-4-fold better than to the 30-bp DNA with the single 1,3d(GpXpG) cisplatin-DNA adduct (filled
circles). Interestingly, the level of rhRPA binding to the 8 base
bubble substrate with a 1,3d(GpXpG) cisplatin-DNA adduct (open
squares) is lower than that of the undamaged 8-base bubble
substrate (filled squares). This data suggests that rhRPA is
binding via the structural distortion in the damaged DNA and not
specifically interacting with the cisplatin-DNA adduct. It also
suggests that the cisplatin-DNA adduct may inhibit the binding of rhRPA
to the damaged DNA strand.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
rhRPA binding to single-stranded DNA in
partial duplex substrates is inhibited by a cisplatin adduct.
A, EMSAs were performed as described previously using a
30-bp undamaged substrate with an 8-base bubble (lanes 1-5)
or the same 8-base bubble substrate with a single 1,3d(GpXpG)
cisplatin-DNA adduct (lanes 6-10). Reactions were incubated
with the indicated amounts of rhRPA in the presence of 2 mM
MgCl2 and 50 mM NaCl. Lanes 1 and
6, without added rhRPA; lanes 2 and 7,
25 ng (212 fmol); lanes 3 and 8, 50 ng (425 fmol); lanes 4 and 9, 100 ng (850 fmol);
lanes 5 and 10, 200 ng (1.7 pmol). The products
were separated on a 4% native polyacrylamide gel. B,
quantification of increasing rhRPA concentrations binding a duplex
30-bp substrate with a 1,3d(GpXpG) cisplatin-DNA adduct ( ), a 30-bp
undamaged substrate with an 8-base bubble ( ), or the same 30-bp
bubble substrate with a single 1,3d(GpXpG) cisplatin-DNA adduct ( ).
The results presented are the average and S.D. from three individual
experiments.
|
|
rhRPA Preferentially Binds an Undamaged Single-stranded DNA
Compared with the Same DNA with a Single 1,2d(GpG) Cisplatin-DNA
Adduct--
To better understand the binding mechanism of rhRPA to
cisplatin-damaged DNA, a single-stranded 24-mer DNA was used in an EMSA
to test the hypothesis that rhRPA binding is inhibited by a
cisplatin-DNA adduct on single-stranded DNA (Fig.
7A). Increasing rhRPA
concentrations were added to 50 fmol of an undamaged single-stranded 24-mer DNA (lanes 1-5) or the same DNA with a single
1,2d(GpG) cisplatin-DNA adduct (lanes 6-10). Quantification
of the EMSA shown in Fig. 7B reveals that rhRPA binds
3-4-fold better to the undamaged single-stranded DNA (open
circles) compared with the same DNA with a single 1,2d(GpG)
cisplatin-DNA adduct (filled circles). This supports the
hypothesis that rhRPA is binding and recognizing the DNA distortion in
duplex DNA and not specifically the cisplatin-DNA adduct. The data also
support a model where following recognition of DNA damage by sensing
the thermal instability of the duplex DNA, RPA binds preferentially to
the undamaged strand of the duplex damaged DNA (Fig.
8).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 7.
Single-stranded DNA binding activity of rhRPA
is inhibited by a single 1,2d(GpG) cisplatin-DNA adduct.
A, EMSAs were performed using the following indicated
amounts of rhRPA and 50 fmol of either undamaged (lanes
1-6) or cisplatin-damaged (lanes 6-10) single-strand
24-mer DNA in the presence of 50 mM NaCl. Lanes
1 and 6, without added rhRPA; lanes 2 and
7, 2.5 ng (21 fmol); lanes 3 and 8, 5 ng (42 fmol); lanes 4 and 9, 10 ng (84 fmol);
lanes 5 and 10, 20 ng (168 fmol). B,
quantification of increasing rhRPA concentrations binding undamaged
( ) or cisplatin-damaged ( ) single-strand 24-mer DNA; the results
presented are the average of two individual experiments, and
error bars represent the range of values.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
Model of RPA binding cisplatin-damaged
DNA. Our data support a model in which RPA binds duplex
cisplatin-damaged DNA, denatures the duplex region around the adduct
and then binds the single-stranded DNA opposite the adduct. Binding the
undamaged strand with a defined polarity (24) positions the XPG and
XPF/ERCC1 nucleases to incise 3' and 5', respectively, on the strand
containing the cisplatin-DNA adduct. Positioning of the TFIIH complex
and XPC-HHR23B remains to be elucidated and have been omitted from this
model for clarity.
|
|
 |
DISCUSSION |
The process of NER is capable of recognizing and repairing a wide
array of bulky DNA damage. The rates of repair of the different DNA-adducts also vary dramatically. The limiting step in NER has been
reported to be incision of the damage, which is completely dependent on
recognizing the damaged DNA in a background of a vast amount of
undamaged chromosomal DNA (reviewed in Ref. 11). The efficiency of NER
has been correlated with the thermodynamic instability of the DNA
duplex caused by the individual DNA adducts (39). As the recognition of
DNA damage limits the reactions and a correlation between repair and
thermal stability of the duplex has been established, one would expect
that proteins involved in the initial recognition would show a
preference for binding damaged DNA with a lower thermal stability. Our
data support this hypothesis, and we have demonstrated that the
affinity for damaged DNA correlates with the thermal instability of the
duplex DNA. RPA binding to a DNA containing a single 1,3d(GpXpG)
cisplatin adduct is more efficient than binding to a 1,2d(GpG)
cisplatin adduct (Fig. 5). These data correlate well with the degree of DNA instability caused by each adduct, since the 1,3 adduct results in
a localized denaturation of the duplex around the adduct, while the
structure of the 1,2 adduct results in the platinated guanines being
within hydrogen bonding distance with the complementary cytosines (38,
36). Also, our previous data demonstrated that conditions that increase
the stability of the duplex DNA inhibit RPA binding, for example, ionic
strength of the binding reactions (25). In addition, we have shown a
single interstrand cisplatin cross-link, which prevents denaturation of
the duplex DNA, effectively inhibits RPA binding (Fig. 3). These data
are consistent with RPA being involved in the initial recognition of
cisplatin-damaged DNA and targeting repair to the damaged site.
RPA has been reported to have an affinity for duplex DNA 3 orders of
magnitude less than that for single-stranded DNA (reviewed in Ref. 40).
Our data demonstrate that binding observed in EMSAs proceeds via the
denaturation of the duplex DNA substrate. This is consistent with the
reported unwinding activity of RPA (32, 33) and our data measuring
denaturation of the duplex undamaged or cisplatin-damaged DNA substrate
(Fig. 4). Our data suggest that the protein-DNA complexes observed in
EMSAs are in fact RPA complexed to single-stranded DNA that was
generated via denaturation of the duplex DNA and that the intermediate
in the reaction representing the RPA-duplex DNA is not stable through
electrophoresis. Therefore, dissociation constants calculated for
duplex DNA may represent the ability to denature and not actual
affinity for the RPA-duplex DNA complex. Our data suggest that
following RPA-induced denaturation of the duplex-damaged DNA, RPA
preferentially binds to the undamaged DNA strand. This was demonstrated
in reactions measuring binding of RPA to a 24-base DNA in the presence
and absence of a centrally located single cisplatin-DNA adduct. While
RPA binding to the platinated DNA was reduced by more than 50% when
compared with the undamaged DNA, significant binding was observed to
the platinated single-stranded DNA substrate. This could be the result
of RPA binding to the regions of the DNA without the adduct, as 11 bases on either side of the adduct are available for high affinity
binding. RPA binding to the bubble substrates also support the
hypothesis that rhRPA is recognizing the structural distortion in the
DNA and not the damaged bases specifically. The decrease in binding the
bubble substrate containing the 1,3 adduct is less than that observed
with the single-stranded 24-base DNA. This is likely the result of high
molar ratio of RPA to duplex DNA necessary to denature the DNA. Once
the duplex substrate is denatured, rhRPA can then bind to the
single-stranded undamaged strand, which is not labeled and is never
detected, as well as to the labeled single-stranded damaged DNA strand.
The excess rhRPA could then bind the single-stranded DNA flanking the
damaged site, which is 14 bases on either side, resulting in the
observed RPA-DNA complex. Consistent with this interpretation, we have
observed consistently greater binding activity to the duplex
cisplatin-damaged DNA substrate when the complementary, undamaged DNA
strand is labeled (data not shown). These data represent the first
direct evidence that RPA regulates DNA repair by binding to
duplex-damaged DNA, locally denaturing the duplex DNA as a result of
the DNA damage, and then binding to the undamaged DNA strand.
Our model positioning RPA on the undamaged DNA is consistent with a
recent report demonstrating that RPA binds single-stranded DNA with a
defined polarity and inhibits cleavage by the XPG and the XPF-ERCC1
endonucleases on the strand that RPA is bound (24). The crystal
structure of RPA bound to an oligonucleotide also suggests some level
of RPA binding polarity (41). Positioning of RPA on the undamaged DNA
strand and the defined polarity of binding also positions the other
repair factors in the proper orientation for their known enzymatic
activities. The N terminus of the 70-kDa subunit of RPA interacts with
XPG (19), and the 34-kDa subunit of RPA interacts with the XPA protein
(20). The XPF protein has also been shown to interact with RPA (22).
These interactions would place XPG 3' of the cisplatin adduct where it
has been shown to incise and the XPF-ERCC1 nuclease 5' of the adduct
where it has been shown to incise (reviewed in Ref. 11). In addition,
binding the undamaged strand by RPA would protect the strand from
nuclease incision as has been demonstrated using undamaged synthetic
DNA substrates. It will be interesting to determine the possible strand
specificity of XPA protein binding when complexed with RPA. In
addition, how the TFIIH and XPC-HHR23B components of the NER machinery
fit in this model remains to be determined.
 |
ACKNOWLEDGEMENTS |
We thank Karen Henkels for excellent
technical assistance and critical reading of the manuscript and Marc
Wold for the RPA expression vector.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA64374 (to J. J. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by a predoctoral fellowship from the Wright State
University Biomedical Sciences Ph.D. program.
§
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology, Wright State University, 3640 Colonel Glenn
Highway, Dayton, OH 45435. Tel.: 937-775-2853; Fax: 937-775-3730; E-mail: john.turchi{at}wright.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
NER, nucleotide
excision repair;
RPA, replication protein A;
rhRPA, recombinant human
replication protein A;
EMSA, electrophoretic mobility shift assay;
DRP, damage recognition proteins;
D/N, drug to nucleotide ratio;
XP, xeroderma pigmentosum;
bp, base pair(s);
I.C., interstrand
cross-link.
 |
REFERENCES |
-
Eastman, A.
(1991)
Cancer Treat. Res.
57,
233-249[Medline]
[Order article via Infotrieve]
-
Perez, R. P.,
Hamilton, T. C.,
Ozols, R. F.,
and Young, R. C.
(1993)
Cancer
71,
1571-1580[Medline]
[Order article via Infotrieve]
-
Chu, G.
(1994)
J. Biol. Chem.
269,
787-790[Abstract/Free Full Text]
-
Zamble, D. B.,
and Lippard, S. J.
(1995)
Trends Biochem. Sci.
20,
435-439[CrossRef][Medline]
[Order article via Infotrieve]
-
Brabec, V.,
Kleinwachter, V.,
Butour, J. L.,
and Johnson, N. P.
(1990)
Biophys. Chem.
35,
129-141[CrossRef][Medline]
[Order article via Infotrieve]
-
Rice, J. A.,
Crothers, D. M.,
Pinto, A. L.,
and Lippard, S. J.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4158-4161[Abstract]
-
Bellon, S. F.,
Coleman, J. H.,
and Lippard, S. J.
(1991)
Biochemistry
30,
8026-8035[Medline]
[Order article via Infotrieve]
-
Pil, P. M.,
and Lippard, S. J.
(1992)
Science
256,
234-237[Medline]
[Order article via Infotrieve]
-
Kasparkova, J.,
and Brabec, V.
(1995)
Biochemistry
34,
12379-12387[Medline]
[Order article via Infotrieve]
-
Moggs, J. G.,
Szymkowski, D. E.,
Yamada, M.,
Karran, P.,
and Wood, R. D.
(1997)
Nucleic Acids Res.
25,
480-491[Abstract/Free Full Text]
-
Sancar, A.
(1996)
Annu. Rev. Biochem.
65,
43-81[CrossRef][Medline]
[Order article via Infotrieve]
-
Wood, R. D.,
Robins, P.,
and Lindahl, T.
(1988)
Cell
53,
97-106[Medline]
[Order article via Infotrieve]
-
Aboussekhra, A.,
Biggerstaff, M.,
Shivji, M. K.,
Vilpo, J. A.,
Moncollin, V.,
Podust, V. N.,
Protic, M.,
Hubscher, U.,
Egly, J. M.,
and Wood, R. D.
(1995)
Cell
80,
859-868[Medline]
[Order article via Infotrieve]
-
Mu, D.,
Park, C. H.,
Matsunaga, T.,
Hsu, D. S.,
Reardon, J. T.,
and Sancar, A.
(1995)
J. Biol. Chem.
270,
2415-2418[Abstract/Free Full Text]
-
Matsuda, T.,
Saijo, M.,
Kuraoka, I.,
Kobayashi, T.,
Nakatsu, Y.,
Nagai, A.,
Enjoji, T.,
Masutani, C.,
Sugasawa, K.,
Hanaoka, F.,
Yasui, A.,
and Tanaka, K.
(1995)
J. Biol. Chem.
270,
4152-4157[Abstract/Free Full Text]
-
Li, L.,
Lu, X.,
Peterson, C. A.,
and Legerski, R. J.
(1995)
Mol. Cell. Biol.
15,
5396-5402[Abstract]
-
Jones, C. J.,
and Wood, R. D.
(1993)
Biochemistry
32,
12096-12104[Medline]
[Order article via Infotrieve]
-
Burns, J. L.,
Guzder, S. N.,
Sung, P.,
Prakash, S.,
and Prakash, L.
(1996)
J. Biol. Chem.
271,
11607-11610[Abstract/Free Full Text]
-
He, Z.,
Henricksen, L. A.,
Wold, M. S.,
and Ingles, C. J.
(1995)
Nature
374,
566-569[CrossRef][Medline]
[Order article via Infotrieve]
-
Stigger, E.,
Drissi, R.,
and Lee, S. H.
(1998)
J. Biol. Chem.
273,
9337-9343[Abstract/Free Full Text]
-
Matsunaga, T.,
Park, C. H.,
Bessho, T.,
Mu, D.,
and Sancar, A.
(1996)
J. Biol. Chem.
271,
11047-11050[Abstract/Free Full Text]
-
Bessho, T.,
Sancar, A.,
Thompson, L. H.,
and Thelen, M. P.
(1997)
J. Biol. Chem.
272,
3833-3837[Abstract/Free Full Text]
-
Evans, E.,
Fellows, J.,
Coffer, A.,
and Wood, R. D.
(1997)
EMBO J.
16,
625-638[Abstract/Free Full Text]
-
de Laat, W. L.,
Appeldoorn, E.,
Sugasawa, K.,
Weterings, E.,
Jaspers, N. G.,
and Hoeijmakers, J. H.
(1998)
Genes Dev.
12,
2598-2609[Abstract/Free Full Text]
-
Patrick, S. M.,
and Turchi, J. J.
(1998)
Biochemistry
37,
8808-8815[CrossRef][Medline]
[Order article via Infotrieve]
-
Henricksen, L. A.,
and Wold, M. S.
(1994)
J. Biol. Chem.
269,
24203-24208[Abstract/Free Full Text]
-
Turchi, J. J.,
Li, M.,
and Henkels, K. M.
(1996)
Biochemistry
35,
2992-3000[CrossRef][Medline]
[Order article via Infotrieve]
-
Turchi, J. J.,
Patrick, S. M.,
and Henkels, K. M.
(1997)
Biochemistry
36,
7586-7593[CrossRef][Medline]
[Order article via Infotrieve]
-
Patrick, S. M.,
Henkels, K. M.,
and Turchi, J. J.
(1997)
Biochim. Biophys. Acta
1354,
279-290[Medline]
[Order article via Infotrieve]
-
Turchi, J. J.,
and Bambara, R. A.
(1993)
J. Biol. Chem.
268,
15136-15141[Abstract/Free Full Text]
-
Pil, P. M.,
Chow, C. S.,
and Lippard, S. J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9465-9469[Abstract]
-
Georgaki, A.,
Strack, B.,
Podust, V.,
and Hubscher, U.
(1992)
FEBS Lett.
308,
240-244[CrossRef][Medline]
[Order article via Infotrieve]
-
Treuner, K.,
Ramsperger, U.,
and Knippers, R.
(1996)
J. Mol. Biol.
259,
104-112[CrossRef][Medline]
[Order article via Infotrieve]
-
Iftode, C.,
and Borowiec, J. A.
(1997)
Mol. Cell. Biol.
17,
3876-3883[Abstract]
-
Xu, Y. C.,
and Bremer, H.
(1997)
Nucleic Acids Res.
25,
4067-4071[Abstract/Free Full Text]
-
Takahara, P. M.,
Rosenzweig, A. C.,
Frederick, C. A.,
and Lippard, S. J.
(1995)
Nature
377,
649-652[CrossRef][Medline]
[Order article via Infotrieve]
-
Anin, M. F.,
and Leng, M.
(1990)
Nucleic Acids Res.
18,
4395-4400[Abstract]
-
van Garderen, C. J.,
and van Houte, L. P.
(1994)
Eur. J. Biochem.
225,
1169-1179[Abstract]
-
Gunz, D.,
Hess, M. T.,
and Naegeli, H.
(1996)
J. Biol. Chem.
271,
25089-25098[Abstract/Free Full Text]
-
Wold, M. S.
(1997)
Annu. Rev. Biochem.
66,
61-92[CrossRef][Medline]
[Order article via Infotrieve]
-
Bochkarev, A.,
Pfuetzner, R. A.,
Edwards, A. M.,
and Frappier, L.
(1997)
Nature
385,
176-181[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.